BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
Bioline RX Ltd Ordinary shares (AMEX: BLNEF) Delayed: 0.86 --0 (-0%)
Previous Close $0.86    52 Week High $1.54 
Open $1.64    52 Week Low $1.15 
Day High $0.86    P/E N/A 
Day Low $0.86    EPS $0.00 
Volume 1,500       

Bioline RX Ltd Ordinary shares (AMEX: BLNEF) Delayed: 0.86 --0 (-0%)
Previous Close $0.86    52 Week High $1.54 
Open $1.64    52 Week Low $1.15 
Day High $0.86    P/E N/A 
Day Low $0.86    EPS $0.00 
Volume 1,500       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.26 +0.02 (0.62%)
Previous Close $3.24    52 Week High $1.63 
Open $3.23    52 Week Low $0.71 
Day High $3.45    P/E N/A 
Day Low $3.23    EPS $0.00 
Volume 74,144       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.26 +0.02 (0.62%)
Previous Close $3.24    52 Week High $1.63 
Open $3.23    52 Week Low $0.71 
Day High $3.45    P/E N/A 
Day Low $3.23    EPS $0.00 
Volume 74,144